PYPD — PolyPid Ltd.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1611842 ·
Last close
$4.84
Market Cap
$92.80M
52W High
$5.20
52W Low
$4.01
ADV30
84,515
Next earnings
2026-08-12
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -7,760,000 -7,728,000 19,160,000 8,888,000 10,380,000
Dec 2025 0 -8,530,000 -8,473,000 22,307,000 6,402,000 11,334,000
Sep 2025 0 -7,455,000 -7,451,000 26,841,000 9,669,000 11,476,000
Jun 2025 0 -9,403,000 -9,977,000 37,687,000 17,448,000 17,211,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-301,500,000
Inventory
$1,106,000
Receivables
ST Investments
$6,531,000
EBIT TTM
$-33,290,000
Pretax Income TTM
$-34,164,000
Interest Exp TTM
$1,839,000
Analysts
4

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -32,967,000 -34,169,000 22,307,000 11,334,000 -27,879,000
Dec 2024 0 -28,029,000 -29,022,000 25,220,000 17,536,000 -21,963,000
Dec 2023 0 -22,867,000 -23,865,000 15,372,000 17,468,000 -17,236,000
Dec 2022 0 -38,888,000 -39,557,000 25,971,000 20,142,000 -34,317,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-1.25

Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)

max pain strike: $5.00 · spot: $4.84 · call volume: 22 · put volume: 100
Expected Move to 2026-11-20: ±$3.85 (79.55%) — implied range $0.99$8.69 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
SPAI Safe Pro Group Inc. $91.75M $4.45
NRXS Neuraxis, INC $86.69M $7.00
STIM Neuronetics, Inc. $84.90M $1.22
LAKE LAKELAND INDUSTRIES INC $104.98M $10.65
OM Outset Medical, Inc. $81.56M $4.40

News headlines (Yahoo Finance, 1h cache)

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
2026-05-20 12:30 · Yahoo
PolyPid Ltd (PYPD) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
2026-05-13 23:01 · Yahoo
PolyPid Ltd. Q1 2026 Earnings Call Summary
2026-05-13 20:58 · Yahoo
PolyPid (PYPD) Q1 2026 Earnings Transcript
2026-05-13 19:01 · Yahoo
PolyPid Q1 Earnings Call Highlights
2026-05-13 18:09 · Yahoo
PolyPid Q1 2026 Earnings Call: Complete Transcript
2026-05-13 13:24 · Yahoo
PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results
2026-05-13 11:30 · Yahoo
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026
2026-05-06 12:00 · Yahoo
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting
2026-04-28 12:30 · Yahoo
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
2026-04-13 13:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.